CompletedNCT00086320

A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.

Medication studyAges 18–65

The study in practice

Understand this study

Listed age limits: 18 years to 65 years.

Study clarity

Study start dateMarch 2004

Recruitment status: Completed
Enrollment listed in the registry: 111
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Not clearly listed
Age range: From 18 Years to 65 Years
Official registry ID: NCT00086320
Official title: Show the full official title
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Evaluating Paliperidone Extended Release Tablets in the Prevention of Recurrence in Subjects With Schizophrenia

Completed

Locations not listed

FAQ

Who is behind this study?

The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Paliperidone ER.

Who was this study for?

Listed age limits: 18 years to 65 years.

Explore other studies

Explore HopeStage studies by mental health topic and refine the results to suit your situation.